ArticleRheumatology (Oxford, England)2026
Automated high-resolution CT analysis outperforms visual assessment in predicting interstitial lung disease progression in SSc.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesProgressive interstitial lung disease (ILD) is the leading cause of mortality in SSc. Early recognition of progression is crucial to timely treatment, but reliable early markers are lacking. Automated quantitative analysis of chest high-resolution CT (HRCT) may provide an objective tool to detect early progression. This study aims to compare automated and visual assessment in identifying early SSc-ILD progression and evaluate their predictive value for subsequent functional decline.
methodsIn this retrospective longitudinal study, 33 patients with SSc-ILD underwent HRCT and pulmonary function tests (PFTs) at baseline (T1) and after 1 year (T2; IQR 0.75-2.5 years). PFTs were repeated 12 months after T2 (T3; IQR 9-14.5 months, T3). Two radiologists performed blinded semi-quantitative visual scoring of fibrosis and ground-glass opacity (GGO), while automated analysis was conducted using Thoracic VCAR (GE Healthcare). Associations with PFTs and prediction of functional progression (Erice/INBUILD criteria) and treatment escalation were analysed.
resultsBoth visual and automated analyses detected fibrosis progression (visual: 1.5 → 1.6, P = 0.0005; software: 0.34% → 0.4%, P = 0.01). Only automated analyses identified increases in GGO (15.5% → 15.8%, P = 0.04) and reduced normal lung tissue (75.6% → 73%, P = 0.009). Software-derived parameters correlated strongly with PFT changes, whereas visual scores showed weaker correlations. Early (T1-T2) automatically-detected GGO increases predicted subsequent functional decline at T3 (P = 0.04), with changes >50 ml (8.2%) yielding 81% sensitivity and 77% specificity.
conclusionAutomated quantitative HRCT analysis, but not visual evaluation, predicts long-term functional progression in SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.